Investment Rating - The report indicates a positive investment outlook for the allergic asthma drug industry in China, with a projected compound annual growth rate (CAGR) of 15.6% from 2024 to 2030, leading to a market size of 467 billion yuan by 2030 [5][9][11]. Core Insights - The current treatment landscape for allergic asthma includes a variety of therapies such as inhaled corticosteroids (ICS), allergen immunotherapy (AIT), and biologics targeting type 2 inflammation, suitable for moderate to severe cases [5][6]. - The market for allergic asthma drugs in China is expanding, driven by an increasing patient population exceeding 40 million and a growing demand for innovative treatments that focus on long-term control rather than just symptom relief [9][11]. - The report highlights the rapid development of biologics, with several monoclonal antibodies targeting IL-5, IL-4Rα, and TSLP showing promise in clinical trials, thus diversifying treatment options for severe asthma patients [12][22]. Summary by Sections Treatment Patterns - The treatment modalities for allergic asthma primarily consist of chemical drugs, allergen immunotherapy, and biologics. Biologics are particularly effective for patients with specific biomarkers [5][6]. Market Size and Growth - The Chinese allergic asthma drug market grew from 11.2 billion yuan in 2018 to an estimated 19.6 billion yuan in 2024, with a CAGR of 9.8%. It is expected to reach 46.7 billion yuan by 2030, reflecting a significant increase in demand due to a rising patient base and improved treatment awareness [9][11]. Drug Development - The report notes a diverse pipeline for new drug development in the allergic asthma sector, with multiple candidates in various clinical trial phases targeting different pathways, including IL-5 and TSLP [12][22]. Biologics Overview - Four classes of monoclonal antibodies have been approved for asthma treatment: anti-IgE, anti-IL-5, anti-IL-5R, and anti-TSLP. These biologics are recommended as add-on therapies for patients who remain uncontrolled on standard treatments [12][22]. Future Trends - The report anticipates a "demand upgrade-technology breakthrough-policy empowerment" phase for the allergic asthma drug market in China, aiming to create a comprehensive ecosystem for innovative treatments that cater to all patient demographics [11][12].